Literature DB >> 18029337

Speed of bacterial kill with a fluoroquinolone compared with nonfluoroquinolones: clinical implications and a review of kinetics of kill studies.

Steven J Lichtenstein1, Rudolph S Wagner, Tiffany Jamison, Belinda Bell, David W Stroman.   

Abstract

It is important to rapidly eradicate bacteria in patients with bacterial conjunctivitis in order to decrease disease transmission, shorten symptom duration, and minimize the emergence of resistant bacteria. This paper presents the results of kinetics of kill studies on 3 commonly isolated pathogens in bacterial conjunctivitis. A more rapid speed of kill with moxifloxacin compared with other nonfluoroquinolone antibiotics (tobramycin, gentamicin, polymyxin B/trimethoprim, or azithromycin) was observed in Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae infections. Moxifloxacin achieved a 99.9% kill at approximately 1 h for S aureus, 2 h for S pneumoniae, and 30 min for H influenzae. In comparison, other nonfluoroquinolone therapies took longer to achieve a bactericidal (3-log) kill and some demonstrated no change or an increase in bacterial growth. Based on these findings, it is concluded that moxifloxacin kills bacteria more rapidly than nonfluoroquinolone topical ocular antibiotics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18029337     DOI: 10.1007/bf02877716

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  8 in total

1.  Susceptible, intermediate, and resistant - the intensity of antibiotic action.

Authors:  Arne Rodloff; Torsten Bauer; Santiago Ewig; Peter Kujath; Eckhard Müller
Journal:  Dtsch Arztebl Int       Date:  2008-09-26       Impact factor: 5.594

2.  Development of a Broad-Spectrum Antimicrobial Combination for the Treatment of Staphylococcus aureus and Pseudomonas aeruginosa Corneal Infections.

Authors:  Michaelle Chojnacki; Alesa Philbrick; Benjamin Wucher; Jordan N Reed; Andrew Tomaras; Paul M Dunman; Rachel A F Wozniak
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

3.  The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.

Authors:  Jose Benitez-Del-Castillo; Yves Verboven; David Stroman; Laurent Kodjikian
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 4.  Moxifloxacin 0.5% ophthalmic solution: in bacterial conjunctivitis.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

5.  Antimicrobial Activity of a Triple Antibiotic Combination Toward Ocular Pseudomonas aeruginosa Clinical Isolates.

Authors:  Jia A Mei; William Johnson; Bailey Kinn; Emily Laskey; Lydia Nolin; Pratham Bhamare; Charlotte Stalker; Paul M Dunman; Rachel A F Wozniak
Journal:  Transl Vis Sci Technol       Date:  2022-05-02       Impact factor: 3.048

6.  Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicin.

Authors:  Rudolph S Wagner; David B Granet; Steven J Lichtenstein; Tiffany Jamison; Joseph J Dajcs; Robert D Gross; Paul Cockrum
Journal:  Clin Ophthalmol       Date:  2010-02-02

7.  Efficacy of a Novel Ophthalmic Antimicrobial Drug Combination Toward a Large Panel of Staphylococcus aureus Clinical Ocular Isolates From Around the World.

Authors:  Emily Laskey; Yimin Chen; Michael B Sohn; Emma Gruber; Michaelle Chojnacki; Rachel A F Wozniak
Journal:  Cornea       Date:  2020-10       Impact factor: 3.152

8.  Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics.

Authors:  Joseph S Bertino
Journal:  Clin Ophthalmol       Date:  2009-09-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.